Dmitry Balyasny’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$38.5M Buy
+949,150
New +$40.3M 0.05% 496
2026
Q1
– Sell
-151,905
Closed -$3.77M – 3069
2025
Q4
$3.77M Buy
+151,905
New +$3.05M ﹤0.01% 1539
2025
Q2
– Sell
-120,910
Closed -$2.66M – 2976
2025
Q1
$2.66M Buy
120,910
+97,546
+418% +$2.56M ﹤0.01% 1567
2024
Q4
$624K Buy
+23,364
New +$744K ﹤0.01% 2118
2024
Q3
– Sell
-528,594
Closed -$9.5M – 2862
2024
Q2
$9.5M Buy
+528,594
New +$9.22M 0.02% 908
2023
Q3
– Sell
-20,660
Closed -$160K – 2386
2023
Q2
$160K Buy
20,660
+5,420
+36% +$45.7K ﹤0.01% 2090
2023
Q1
$102K Sell
15,240
-3,100
-17% -$28.7K ﹤0.01% 2313
2022
Q4
$164K Buy
+18,340
New +$172K ﹤0.01% 2171

Other funds holding EWTX

Dmitry Balyasny's EWTX Position: Q3 2026 in Review

Dmitry Balyasny opened a new position in Edgewise Therapeutics (EWTX) in Q3 2026: 949,150 shares worth $38.5M. The stake represents 0.05% of the portfolio and ranks #496 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in EWTX as recently as Q4 2025.

Dmitry Balyasny first reported a position in EWTX in Q4 2022 and has held it in 8 quarters since. 249 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

  • Dmitry Balyasny held 949,150 shares of Edgewise Therapeutics worth $38.5M as of Q3 2026.
  • Edgewise Therapeutics was a new Dmitry Balyasny position in Q3 2026.
  • Edgewise Therapeutics made up 0.05% of Dmitry Balyasny's portfolio in Q3 2026, its #496 holding.
  • Dmitry Balyasny first reported a position in Edgewise Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 249 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.